Treating non-clear cell renal cell carcinoma (RCC) is challenging because these diseases are rare, and so far there are no effective treatments for this group of patients. Non-clear cell RCC is currently treated in a similar way to clear cell RCC. In a phase 2 clinical trial, 31 patients with non-clear cell RCC were treated […]
In this phase 2 clinical trial, a combination of everolimus plus bevacizumab was looked at in 37 patients with papillary renal cell carcinoma (RCC). The study showed that the combination was effective and delayed progression of the disease (progression-free survival) on average for 13.7 months. There was a response rate of 35%, and overall survival […]
A new combination of vorolanib, a tyrosine kinase inhibitor plus everolimus, an mTOR inhibitor shows promise for the treatment of advanced renal cell carcinoma (RCC). A phase 1 study looking at how well the combination is tolerated by patients, safety (side effects), and how the combination works in the body, has shown some promise. Twenty-two […]
A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) inhibitor, MK-6482, was announced at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. HIF-2α is known to stimulate the growth of tumours via the von Hippel-Lindau (VLH) group of genes. MK-6482 (also known as PT2977) blocks the […]
Five-year follow-up results from the phase 3 CheckMate-025 study, which compared nivolumab (Opdivo) with everolimus in previously treated advanced or metastatic renal cell carcinoma (RCC), were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. Nivolumab continues to show superior overall survival and objective response rates […]
The US Food and Drug Administration (FDA) has approved generic everolimus tablets for the treatment of patients with various advanced cancers, including renal cell carcinoma (RCC). Afinitor comes off patent over the next 5 years, after which generic everolimus will become available at a vastly cheaper cost to the NHS. A generic drug is a pharmaceutical drug that contains […]
A recent phase I clinical trial assessed the combination of everolimus (an mTOR inhibitor) with panobinostat (a histone deacetylase inhibitor) in 21 patients with clear-cell metastatic renal cell carcinoma (RCC) who had disease progression within 6 months of stopping treatment with VEGFR TKIs. Median progression-free survival was 4.1 months. Anaemia and thrombocytopenia were the most […]
We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of lenvatinib plus everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy by NHS Scotland. The lenvatinib plus everolimus combination was accepted following consideration […]
Results from the ENTRATA clinical trial to assess telaglenastat in combination with everolimus for patients with heavily pre-treated renal cell carcinoma were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Telaglenastat is a type of biological therapy called a glutaminase inhibitor that blocks the glutaminase enzyme, which is […]
A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy. Positive expression of the PD-L1 receptor on RCC tumour cells was associated […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
